CommercialAdministrativeLow impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Urology·Medical Policy
Effective date
Apr 9, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross is archiving three medical policies effective April 9, 2026: Antineoplaston Cancer Therapy, PDE-5 Inhibitors for Benign Prostatic Hypertrophy, and Droxidopa. These policies will no longer be active after the effective date.
Action Required
Before April 9, 2026: Billing team should review current claims for Antineoplaston cancer therapy, PDE-5 inhibitors for benign prostatic hypertrophy (e.g., tadalafil), and Droxidopa (Northera) to understand any coverage changes. Access the full archived policies via the provided Arkansas Blue Cross links to determine alternative coverage pathways or updated guidelines.